Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged In Phase II/III Marvel Trial Of Myogenic Cells For Treating Advanced Heart Failure

Bioheart, Inc., (Nasdaq: BHRT), announced that 35 of the leading U.S. Heart Failure Centers have engaged in Bioheart's Phase II/III MARVEL(1) Trial of myogenic cells for treating advanced heart failure. "With 35 leading heart failure centers engaged, we are making tremendous progress in patient screening and enrollment," said Dr.

Evalve Announces Enrollment Completion Of The EVEREST Randomized Study

Evalve, Inc., the leader in the development of devices for the percutaneous repair of cardiac valves, announced the completion of randomized enrollment in the Endovascular Valve Edge-to-Edge REpair STudy (EVEREST), which is evaluating the MitraClip(R) system as a non-surgical repair option for patients suffering from mitral regurgitation (MR). MR is the most common type of heart valve insufficiency in the United States, affecting millions of people worldwide.

Indevus Announces Agreement With Teva To Develop Pagoclone For The Treatment Of Stuttering

Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced that it has signed a development, license and commercialization agreement with Teva Pharmaceutical Industries Ltd. for the exclusive, worldwide rights to pagoclone.

New Information On Hormone Replacement Therapy And The Risk Of Heart Attacks Provided By Danish Study

It's not what you take but the way that you take it that can produce different results in women who take hormone replacement therapy (HRT), according to new research on the association between HRT and heart attacks, published online in Europe's leading cardiology journal, the European Heart Journal [1] today (Wednesday 1 October).

Stratatech Successfully Completes Clinical Trial Of StrataGraft^ Skin Substitute - Trial's Primary Clinical Endpoint Achieved

Stratatech Corp. , a regenerative medicine company focused on the development and commercialization of cell-based, tissue-engineered skin substitute products, today announced that it has successfully completed the multi-center, 15-patient clinical trial of its StrataGraft^

Cervical Dystonia - FDA's First-Cycle Review Of Dysport(R) To Be Completed By Year-End

Ipsen (Paris:IPN) announced that the U.S. Food and Drug Administration (FDA) provided notification that the Prescription Drug User Fee Act (PDUFA) action date for Dysport^ (botulinum toxin of type A) Biologics License Application (BLA) for the treatment of patients with cervical dystonia has been extended to no later than 28 December 2008. This regulatory decision will not impact the anticipated company launch plan timing.

A.P. Pharma Announces Positive Phase 3 Results With APF530 In The Prevention Of Chemotherapy Induced Nausea And Vomiting

A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, announced today positive results from its pivotal Phase 3 study comparing te efficacy of APF530 (the Company's proprietary, sustained release formulation of granisetron) with Aloxi^ for the prevention of chemotherapy induced nausea and vomiting (CINV).